We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of OPC-262 in Patients With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00997282
Recruitment Status : Completed
First Posted : October 19, 2009
Last Update Posted : January 8, 2014
Sponsor:
Information provided by:
Kyowa Hakko Kirin Co., Ltd

Brief Summary:
The purpose of this clinical study is to evaluate the superiority of the efficacy of OPC-262 (2.5 mg, and 5 mg) to placebo in patients with type 2 diabetes after 24 week treatment in a double-blind fashion and to evaluate the safety of OPC-262 to placebo.

Condition or disease Intervention/treatment Phase
Diabetes Type 2 Drug: OPC-262 2.5 mg Drug: OPC-262 5 mg Drug: Placebo Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 255 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-arms Parallel Group Comparative Study of OPC-262 in Patients With Type 2 Diabetes (Phase 2/3 Study)
Study Start Date : September 2009
Primary Completion Date : October 2010
Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: OPC-262 2.5 mg
orally administered once daily for 24 weeks
Drug: OPC-262 2.5 mg
orally administered once daily for 24 weeks
Experimental: OPC-262 5 mg
orally administered once daily for 24 weeks
Drug: OPC-262 5 mg
orally administered once daily for 24 weeks
Placebo Comparator: Placebo
orally administered once daily for 24 weeks
Drug: Placebo
orally administered once daily for 24 weeks



Primary Outcome Measures :
  1. Changes in HbA1C from baseline [ Time Frame: Week 24 (LOCF) ]

Secondary Outcome Measures :
  1. Changes in fasting blood glucose (FBG) from baseline [ Time Frame: Week 24 ]
  2. Changes in 2 hour postprandial blood glucose (PPG) from baseline [ Time Frame: Week 24 ]
  3. Changes in 3 hour PPG AUC from baseline [ Time Frame: Week 24 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Type 2 diabetes patients with HbA1C above 6.5% and below 10%
  2. Patients who are capable of giving informed consent
  3. Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner for the entire study period and for 4 weeks after the study (end of the post-observation period)

Exclusion Criteria:

  1. Patients with type 1 diabetes mellitus, patients with diabetes mellitus due to other specified drugs, mechanisms or diseases, and patients with gestational diabetes mellitus
  2. Patients with a medical history of diabetic coma
  3. Patients with poorly-controlled hypertension
  4. Patients with heart failure
  5. Patients with a complication of active hepatitis or hepatic cirrhosis
  6. Patients undergoing treatment of glomerular diseases other than diabetic nephropathy
  7. Patients with a history or complication of malignant tumor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00997282


Locations
Japan
Chubu Region, Japan
Chugoku Region, Japan
Kansai Region, Japan
Kanto Region, Japan
Kyushu Region, Japan
Shikoku Region, Japan
Tohoku Region, Japan
Sponsors and Collaborators
Kyowa Hakko Kirin Co., Ltd
Investigators
Study Chair: Kaatsuhisa Saito OPCJ

Responsible Party: Katsuhisa Saito, Senior Operating Officer, Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT00997282     History of Changes
Other Study ID Numbers: 262-09-001
JapicCTI-090904
First Posted: October 19, 2009    Key Record Dates
Last Update Posted: January 8, 2014
Last Verified: January 2014

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases